Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Decrease in Breast-Cancer Incidence in 2003 in the United States

The Decrease in Breast-Cancer Incidence in 2003 in the United States An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the United States fell sharply (by 6.7%) in 2003, as compared with the rate in 2002. Data from 2004 showed a leveling off relative to the 2003 rate, with little additional decrease. Regression analysis showed that the decrease began in mid-2002 and had begun to level off by mid-2003. A comparison of incidence rates in 2001 with those in 2004 (omitting the years in which the incidence was changing) showed that the decrease in annual age-adjusted incidence was 8.6% (95% confidence interval [CI], 6.8 to 10.4). The decrease was evident only in women who were 50 years of age or older and was more evident in cancers that were estrogen-receptor–positive than in those that were estrogen-receptor–negative. The decrease in breast-cancer incidence seems to be temporally related to the first report of the Women's Health Initiative and the ensuing drop in the use of hormone-replacement therapy among postmenopausal women in the United States. The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The New England Journal of Medicine The New England Journal of Medicine

Loading next page...
 
/lp/the-new-england-journal-of-medicine/the-decrease-in-breast-cancer-incidence-in-2003-in-the-united-states-tyfIaY0jyx

References (17)

  • J. Rossouw, G. Anderson, Ross Prentice, Andrea LaCroix, C. Kooperberg, M. Stefanick, R. Jackson, Shirley Beresford, Barbara Howard, Karen Johnson, J. Kotchen, Judith Ockene (2002)

    Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

    JAMA, 288 3

  • P. Porter, A. El-Bastawissi, M. Mandelson, M. Lin, N. Khalid, Elizabeth Watney, Laura Cousens, D. White, S. Taplin, E. White (1999)

    Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.

    Journal of the National Cancer Institute, 91 23

  • B. Edwards, Martin Brown, P. Wingo, H. Howe, Elizabeth Ward, L. Ries, D. Schrag, P. Jamison, A. Jemal, X. Wu, C. Friedman, L. Harlan, J. Warren, Robert Anderson, L. Pickle (2005)

    Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.

    Journal of the National Cancer Institute, 97 19

  • A. Hersh, M. Stefanick, R. Stafford (2004)

    National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

    JAMA, 291 1

  • D. Buist, K. Newton, D. Miglioretti, Kevin Beverly, M. Connelly, S. Andrade, C. Hartsfield, F. Wei, Arnold Chan, L. Kessler (2004)

    Hormone Therapy Prescribing Patterns in the United States

    Obstetrics & Gynecology, 104

  • A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, M. Thun (2007)

    Cancer Statistics, 2007

    CA: A Cancer Journal for Clinicians, 57

  • Eugenia Calle, C. Heath, R. Coates, J. Liff, Silvia Franceschi, R. Talamini, N. Chantarakul, Suporn Koetsawang, D. Rachawat, A. Morabia, L. Schuman, W. Stewart, M. Szklo, Chris Bain, F. Schofield, Victor Siskind, P. Band, A. Coldman, Richard Gallagher, T. Hislop, P. Yang, Stephen Duffy, Laurence Kolonel, A. Nomura, M. Oberle, H. Ory, Herbert Peterson, H. Wilson, P. Wingo, K. Ebeling, D. Kunde, P. Nishan, Graham Colditz, Nicholas Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. McMichael, T. Rohan, M. Ewertz, Carle Paul, D. Skegg, G. Spears, Peter Boyle, M. Evstifeeva, J. Daling, W. Hutchinson, K. Malone, E. Noonan, J. Stanford, D.B. Thomas, N. Weiss, E. White, Nadine Andrieu, A. Bràmond, F. Clavel, B. Gairard, J. Lansac, L. Piana, R. Renaud, S. Fine, H. Cuevas, P. Ontiveros, A. Palet, S. Salazar, N. Aristizabel, A. Cuadros, A. Bachelot, M. Lê, J. Deacon, J. Peto, C. Taylor, E. Alfandary, Baruch Modan, Elaine Ron, G. Friedman, Robert Hiatt, T. Bishop, J. Kosmelj, M. Primic‐Žakelj, B. Ravnihar, J. Stare, W. Beeson, Graeme Fraser, R. Bulbrook, J. Cuzick, I. Fentiman, J. Hayward, D. Wang, R. Hanson, M. Leske, M. Mahoney, P. Nasca, A. Varma, A. Weinstein, Torgil Möller, Hampus Olsson, J. Ranstam, R. Goldbohm, P. Brandt, R. Apelo, J. Baens, J. Cruz, B. Javier, L. Lacaya, C. Ngelangel, C. Vecchia, E. Negri, Ettore Marubini, M. Ferraroni, Mariette Gerber, S. Richardson, C. Ségala, D. Gatei, P. Kenya, A. Kungu, J. Mati, L. Brinton, R. Hoover, C. Schairer, R. Spirtas, H. Lee, M. Rookus, F. Leeuwen, J. Schoenberg, M. Gammon, E. Clarke, L. Jones, Klim McPherson, A. Neil, M. Vessey, D. Yeates, V. Beral, D. Bull, B. Crossley, C. Hermon, S. Jones, Timothy Key, C. Lewis, G. Reeves, R. Collins, R. Doll, R. Peto, P. Hannaford, CliffordR. Kay, L. Rosero-Bixby, Jian-Min Yuan, H. Wei, T. Yun, C. Zhiheng, G. Berry, J. Booth, T. Jelihovsky, R. Maclennan, R. Shearman, Q. Wang, C. Baines, A. Miller, C. Wall, E. Lund, H. Stalsberg, A. Dabancens, L. Martínez, R. Molina, O. Salas, Freda Alexander, B. Hulka, C. Chilvers, L. Bernstein, R. Haile, A. Paganini-Hill, M. Pike, R. Ross, G. Ursin, Mimi Yu, M. Longnecker, P. Newcomb, T. Farley, S. Holck, O. Meirik, H. Adami, R. Bergkvist, I. Persson, F. Levi, Kiyohiko Mabuchi, D. Preston, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, L. Bergkvist (1997)

    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

    The Lancet, 350

  • (2004)

    Tamoxifen use for breast cancer chemoprevention among U . S . women

  • (2006)

    A sharp decrease in breast cancer incidence in the United States in 2003

  • R. Prasad, G. Boland, A. Cramer, E. Anderson, W. Knox, N. Bundred (2003)

    Short‐term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma

    Cancer, 98

  • T. Powles, T. Hickish (1995)

    Breast cancer response to hormone replacement therapy withdrawal

    The Lancet, 345

  • H. Howe, Xiaocheng Wu, L. Ries, V. Cokkinides, F. Ahmed, A. Jemal, B. Miller, Melanie Williams, Elizabeth Ward, P. Wingo, Amelie Ramirez, B. Edwards (2006)

    Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations

    Cancer, 107

  • C. Clarke, S. Glaser, Connie Uratsu, J. Selby, L. Kushi, L. Herrinton (2006)

    Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 33

  • D. Berry, K. Cronin, S. Plevritis, D. Fryback, L. Clarke, M. Zelen, J. Mandelblatt, A. Yakovlev, J. Habbema, E. Feuer (2006)

    Effect of screening and adjuvant therapy on mortality from breast cancer.

    The New England journal of medicine, 353 17

  • O. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama, H. Masuda, Y. Nomura, K. Sakai, K. Sugimachi, T. Tominaga, J. Uchino, M. Yoshida, J. Haybittle, C. Davies, V. Harvey, TM Holdaway, R. Kay, B. Mason, J. Forbes, N. Wilcken, M. Gnant, R. Jakesz, M. Ploner, H. Yosef, C. Focan, J. Lobelle, U. Peek, G. Oates, J. Powell, M. Durand, L. Mauriac, A. Leo, S. Dolci, M. Piccart, M. Masood, D. Parker, J. Price, P. Hupperets, S. Jackson, J. Ragaz, D. Berry, G. Broadwater, C. Cirrincione, H. Muss, L. Norton, R. Weiss, H. Abu‐Zahra, S. Portnoj, M. Baum, J. Cuzick, J. Houghton, D. Riley, NH Gordon, H. Davis, A. Beatrice, J. Mihura, A. Naja, Y. Lehingue, P. Romestaing, JB Dubois, T. Delozier, J. Macé-Lesec’h, P. Rambert, O. Andrysek, J. Barkmanova, Owen, P. Meier, A. Howell, G. Ribeiro, R. Swindell, R. Alison, J. Boreham, M. Clarke, R. Collins, S. Darby, P. Elphinstone, Evans, J. Godwin, R. Gray, C. Harwood, C. Hicks, S. James, E. Mackinnon, P. Mcgale, T. McHugh, G. Mead, R. Peto, Y. Wang, J. Albano, Cf Oliveira, H. Gervásio, J. Gordilho, H. Johansen, H. Mouridsen, R. Gelman, Harris, I. Henderson, Claire Shapiro, K. Andersen, C. Axelsson, M. Blichert‐Toft, S. Møller, J. Overgaard, M. Overgaard, C. Rose, B. Cartensen, T. Palshof, H. Trampisch, O. Dalesio, D. Vries, S. Rodenhuis, H. Tinteren, R. Comis, N. Davidson, N. Robert, G. Sledge, D. Tormey, W. Wood, D. Cameron, U. Chetty, P. Forrest, W. Jack, J. Rossbach, J. Klijn, A. Treurniet‐Donker, W. Putten, Alberto Costa, U. Veronesi, H. Bartelink, L. Duchateau, C. Legrand, R. Sylvester, J. Hage, C. Velde, M. Cunningham, R. Catalano, R. Creech, J. Bonneterre, P. Fargeot, P. Fumoleau, P. Kerbrat, M. Namer, W. Jonat, M. Kaufmann, M. Schumacher, G. Minckwitz, G. Bastert, H. Rauschecker, R. Sauer, W. Sauerbrei, A. Schauer, A. Schryver, L. Vakaet, M. Belfiglio, A. Nicolucci, F. Pellegrini, M. Sacco, M. Valentini, C. McArdle, D. Smith, E. Galligioni, F. Boccardo, A. Rubagotti, D. Dent, C. Gudgeon, A. Hacking, A. Erazo, J. Medina, M. Izuo, Y. Morishita, H. Takei, I. Fentiman, J. Hayward, R. Rubens, D. Skilton, H. Graeff, F. Jänicke, C. Meisner, H. Scheurlen, D. Fournier, U. Dafni, G. Fountzilas, P. Klefstrom, C. Blomqvist, T. Saarto, R. Margreiter, B. Asselain, R. Salmon, Vilcoq, R. Arriagada, C. Hill, A. Laplanche, M. Lê, M. Spielmann, P. Bruzzi, E. Montanaro, R. Rosso, Sertoli, M. Venturini, D. Amadori, J. Benraadt, M. Kooi, A. Velde, J. Dongen, J. Vermorken, M. Castiglione, F. Cavalli, A. Coates, J. Collins, J. Forbes, R. Gelber, A. Goldhirsch, J. Lindtner, K. Price, C. Rudenstam, H. Senn, J. Bliss, C. Chilvers, R. Coombes, E. Hall, M. Marty, R. Borovik, G. Brufman, H. Hayat, E. Robinson, N. Wigler, G. Bonadonna, T. Camerini, G. Palo, M. Vecchio, F. Formelli, P. Valagussa, A. Martoni, F. Pannuti, G. Cocconi, A. Colozza, R. Camisa, K. Aogi, S. Takashima, T. Ikeda, K. Inokuchi, K. Sawa, H. Sonoo, S. Korzeniowski, J. Skołyszewski, M. Ogawa, J. Yamashita, J. Bonté, R. Christiaens, R. Paridaens, W. Boegart, P. Martin, S. Romain, T. Hakes, C. Hudis, R. Wittes, G. Giokas, D. Kondylis, B. Lissaios, R. Huerta, MG Sainz, R. Altemus, K. Cowan, D. Danforth, A. Lichter, M. Lippman, J. O’Shaughnessy, L. Pierce, S. Steinberg, D. Venzon, J. Zujewski, A. Paradiso, M. Lena, F. Schittulli, J. Myles, J. Pater, K. Pritchard, S. Anderson, G. Bass, Andrew Brown, J. Bryant, J. Costantino, J. Dignam, B. Fisher, C. Redmond, S. Wieand, N. Wolmark, I. Jackson, M. Palmer, J. Ingle, V. Suman, N. Bengtsson, H. Jonsson, L. Larsson, J. Lythgoe, M. Kissin, B. Erikstein, E. Hannisdal, Abby Jacobsen, J. Varhaug, S. Gundersen, M. Hauer-Jensen, H. Høst, R. Nissen-Meyer, R. Blamey, A. Mitchell, D. Morgan, J. Robertson, M. Palma, G. Mathé, J. Misset, R. Clark, M. Levine, K. Morimoto, Y. Takatsuka, E. Crossley, A. Harris, D. Talbot, Marianne Taylor, B. Blasio, Ivanov, Semiglazov, J. Brockschmidt, Cooper, H. Ueo, C. Falkson, R. a'Hern, S. Ashley, T. Powles, I. Smith, Yarnold, Gazet Jc, N. Cocoran, N. Deshpande, L. Martino, P. Douglas, A. Lindtner, G. Notter, Ajs Bryant, G. Ewing, L. Firth, J. Krushen-Kosloski, L. Foster, W. George, H. Stewart, P. Stroner, P. Malmström, T. Möller, S. Rydén, Tengrup, L. Tennvall-Nittby, J. Carstenssen, M. Dufmats, T. Hatschek, B. Nordenskjöld, M. Söderberg, J. Carpenter, K. Albain, James Crowley, S. Green, S. Martino, C. Osborne, P. Ravdin, U. Glas, U. Johansson, L. Rutqvist, T. Singnomklao, A. Wallgren, R. Maibach, B. Thürlimann, H. Brenner, A. Hercbergs, M. Yoshimoto, G. Deboer, A. Paterson, J. Meakin, T. Panzarella, Y. Shan, Y. Shao, Y Wang, DB Zhao, Zm Chen, HC Pan, J. Bahi, M. Reid, M. Spittle, Gp Deutsch, F. Senanayake, D. Kwong, A. Bianco, C. Carlomagno, M. Laurentiis, S. Placido, A. Buzdar, Thomas Smith, J. Bergh, L. Holmberg, G. Liljegren, J. Nilsson, M. Seifert, P. Sevelda, C. Zielinsky, R. Buchanan, M. Cross, G. Royle, J. Dunn, R. Hills, M. Lee, J. Morrison, D. Spooner, A. Litton, R. Chlebowski, H. Caffier, Ebctcg (2005)

    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    The Lancet, 365

  • B. Fisher, J. Costantino, D. Wickerham, C. Redmond, M. Kavanah, W. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-chiu, L. Ford, N. Wolmark (1999)

    Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

    Journal of the National Cancer Institute, 90 18

  • 青儀 健二郎 (2006)

    What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及

    , 3

Publisher
The New England Journal of Medicine
Copyright
Copyright © 2007 Massachusetts Medical Society. All rights reserved.
ISSN
0028-4793
eISSN
1533-4406
DOI
10.1056/NEJMsr070105
pmid
17442911
Publisher site
See Article on Publisher Site

Abstract

An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the United States fell sharply (by 6.7%) in 2003, as compared with the rate in 2002. Data from 2004 showed a leveling off relative to the 2003 rate, with little additional decrease. Regression analysis showed that the decrease began in mid-2002 and had begun to level off by mid-2003. A comparison of incidence rates in 2001 with those in 2004 (omitting the years in which the incidence was changing) showed that the decrease in annual age-adjusted incidence was 8.6% (95% confidence interval [CI], 6.8 to 10.4). The decrease was evident only in women who were 50 years of age or older and was more evident in cancers that were estrogen-receptor–positive than in those that were estrogen-receptor–negative. The decrease in breast-cancer incidence seems to be temporally related to the first report of the Women's Health Initiative and the ensuing drop in the use of hormone-replacement therapy among postmenopausal women in the United States. The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded.

Journal

The New England Journal of MedicineThe New England Journal of Medicine

Published: Apr 19, 2007

There are no references for this article.